Categories
Industry Analysis Market Reports News

Fragment-based Drug Discovery – A Boon in Disguise to get a Breakthrough Drug Against Covid-19 | Roots Analysis

With over 855,000 cases and 42,000 deaths, the novel coronavirus has taken its toll on humanity. The pandemic is predicted to throw the global economy into recession, with loss of trillions of dollars. The pharmaceutical industry cannot escape the brunt of the circumstances as well. In fact, according to a survey, 95% of healthcare industry professionals are worried about the impact the pandemic is likely to have on the industry.

To add fire to the fuel, there is no approved drug to curb the menace caused by the virus. While several agents are being investigated under clinical trials or being used under compassionate use protocols, efficacy has not been established for any drug. With almost the whole world on a lockdown and threat looming over the lives of billions of people, researchers need to find an effective drug at the earliest.

For More Insights Click Here

The road ahead is not easy. Drug discovery and development is a complex and tedious process requiring significant amount of time and resources. In fact, on an average, the entire drug development process (from initial proof-of-concept to commercial launch) takes around 10-15 years and requires huge capital investments (USD 2.6 billion). The world cannot wait for so long to get a cure for the drug. Fragment-based Drug Discovery (FBDD) may prove to be a boon in such testing times. With computational methods gaining widespread acceptance in drug discovery process, the FBDD approach is time-, money-, and labour saving. It is owing to these advantages that several players are offering libraries and services related to FBDD.

Companies Offering Fragment-based Drug Discovery Library and Services

Presently, over 90 firms are involved in providing fragment-based drug discovery-related services; of these, around 30 players claim to offer both libraries and technologies.

Companies providing fragment-based drug discovery library and services, and their geographical distribution

Which company has an edge over other companies?

With so many players in the market, it may become baffling to decide on which company would serve your purpose. Every company has its own unique set of libraries / technology platforms to cater to the needs of its clients. However, some companies do have advantages over other competitors, in terms of their experience and service portfolio. With the intention to develop a better understanding of the overall potential and capabilities of industry players involved in this domain, we carried out a company competitiveness analysis of the various stakeholders across different geographies.

Company Competitiveness Analysis to determine the most prominent players across different geograhies

Eager to know who these prominent players are? Don’t wait, check out the report here.

FBDD is a relatively new approach in the arena of drug discovery. In spite of this, more than 50% of current drug discovery projects are estimated to be using FBDD. In fact, there are already three marketed drugs that used the FBDD approach. Considering the prevalent trend of drug discovery and approval, we are led to believe that the fragment-based approach has the potential to enable significant time and cost savings.

Cost Saving Potential of Fragment-based Drug Discovery

Conclusion

The COVID-19 outbreak has put the whole world under chaos. The stock market is down, strict border controls and country-wide lockdowns has taken a huge toll on the pharmaceutical industry and the health sector at large. The whole world is praying for a solution. All potential candidates are being investigated to find a breakthrough that would put a chain to the pandemic. In such global crisis, FBDD may prove to be a viable option to identify lead compounds at the earliest and get the potential leads into trials.

For further information on this emerging domain, check out the report here.

You may also be interested in the following titles:

  1. Neoantigen Targeted Therapies Market, 2019-2030
  2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
  3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Industry Analysis Market Reports News

Close to 120 companies across the globe claim to possess the required expertise and infrastructure to offer contract manufacturing services for HPAPIs and cytotoxic drugs, claims Roots Analysis

Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug manufacturing facilities. This has led to an increased demand for contract manufacturing service providers in this field.

The USD 25 billion (by 2030) financial opportunity within the hpapi And Cytotoxic Drugs Contract Manufacturing market has been analyzed across the following segments:

Type of Product

  • HPAPIs
  • Highly Potent Finished Dosage Forms

Company Size

  • Small-sized
  • Mid-sized
  • Large / Very Large

Scale of Operation

  • Preclinical / Clinical
  • Commercial

Type of Pharmacological Molecule

  • Small Molecules
  • Biologics

Type of Highly Potent Finished Dosage Form

  • Injectables
  • Oral Solids
  • Creams
  • Others

Key geographical regions

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

For more information, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

The “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030” report features the following companies, which we identified to be key players in this domain:  

  • AbbVie Contract Manufacturing
  • CARBOGEN AMCIS
  • Catalent
  • Evonik
  • Formosa Laboratories
  • Intas
  • Lonza
  • MabPlex
  • Pfizer CentreOne

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Market Landscape
  5. Company Competitive Analysis
  6. HPAPI and Cytotoxic Drugs Contract Manufacturers based in North America: Company Profiles
  7. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe: Company Profiles
  8. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific: Company Profiles
  9. Partnerships and Collaborations
  10. Recent Expansions
  11. Capacity Analysis
  12. Market Sizing and Opportunity Analysis
  13. Case-In-Point: Contract Manufacturing of Antibody Drug Conjugates
  14. Concluding Remarks
  15. Executive Insights
  16. Appendix 1: Tabulated Data
  17. Appendix 2: List of Companies and Organizations

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Categories
Industry Analysis Market Reports News

Over 85 firms are involved in providing fragment-based drug discovery-related services; of these, around 40 players claim to offer both libraries and technologies

According to experts in this field, Fragment-Based Drug Discovery Solutions have facilitated the identification of viable pharmacological leads against otherwise hard to target biomolecules. In fact, many service provider companies are offering fragment libraries and support to the medical research community in order to develop an appropriate intervention to treat the illness caused by the SARS-CoV-2 virus.

The USD 1.6 billion (by 2030) financial opportunity within the fragment-based drug discovery market has been analyzed across the following segments:

Key Market Insights

Type of Screening Technique Used

  • X-ray Crystallography
  • Nuclear Magnetic Resonance
  • Surface Plasmon Resonance
  • Other Screening Techniques

Type of Service Offered

  • Library Screening
  • Fragment Screening
  • Fragment Optimization

End User

  • Industry Players
  • Non-Industry Players

Key geographical regions

  • North America (US and Canada)
  • Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
  • Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)

For more information, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

The Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030 report features the following companies, which we identified to be key players in this domain:  

  • 2bind
  • Charles River Laboratories
  • ChemAxon
  • ComInnex
  • Creative Biolabs
  • Creative Biostructure
  • CRELUX
  • Domainex
  • Evotec
  • Red Glead Discovery
  • SARomics Biostructures
  • Shanghai ChemPartner
  • Sygnature Discovery
  • Vernalis Research

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Current Market Landscape
  5. Company Profiles: Fragment-based Drug Discovery Library and Service Providers
  6. Partnerships and Collaborations
  7. Key Acquisition Targets
  8. Company Competitiveness Analysis
  9. Cost Saving Analysis
  10. Market Forecast and Opportunity Analysis
  11. Executive Insights
  12. Concluding Remarks
  13. Appendix 1: Tabulated Data
  14. Appendix 2: List of Companies and Organizations

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Industry Analysis Market Reports News

Presently, over 150 Neoantigen Targeted Therapies are being evaluated for advanced cancer indications and are designed for delivery via different routes of administration

The use of neoantigens in therapy has demonstrated the ability to elicit a strong T cell mediated immune response. Several therapy candidates are being investigated both as monotherapies and in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab, and nivolumab. Of these, certain pipeline candidates have already entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

The USD 3 billion (by 2030) financial opportunity within the Neoantigens Market has been analyzed across the following segments:

Type of target disease indication

  • Bone cancer
  • Colorectal cancer
  • Gynecological cancer
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Other cancers

Type of neoantigens

  • Personalized neoantigens
  • Off-the-shelf neoantigens

Type of immunotherapy

  • Dendritic cell vaccines
  • DNA / RNA-based vaccines
  • Protein / peptide-based vaccines
  • TIL-based therapies

Route of administration

  • Intradermal
  • Intravenous
  • Subcutaneous
  • Other routes

Key geographical regions

  • North America
  • Europe
  • Rest of the World

The report features inputs from eminent industry stakeholders, according to whom neoantigen targeted therapies are expected to be the next big step in cancer immunotherapy. Similar to CAR-T cell therapies, these therapies have, so far, demonstrated significant therapeutic potential and promising clinical outcomes. The report includes detailed transcripts of discussions held with the following experts:

  • Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)
  • Ella Sorani (Vice President Research and Development, BioLineRx)
  • Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)

The Neoantigen Targeted Therapies, 2019-2030 report features the following companies, which we identified to be key players in this domain:

  • Bavarian Nordic
  • Genocea Biosciences
  • Gradalis
  • Immunicum
  • Immunovative Therapies
  • Iovance Biotherapeutics
  • Medigene
  • Neon Therapeutics
  • Precision Biologics
  • Vaxon Biotech

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Market Overview
  5. Company Profiles: Neoantigen Targeted Therapies
  6. Publication Analysis
  7. Patent Analysis
  8. Partnerships and Collaborations
  9. Funding and Investment Analysis
  10. Market Forecast and Opportunity Analysis
  11. Concluding Remarks
  12. Executive Insights
  13. Appendix 1: Tabulated Data
  14. Appendix 2: List of Companies and Organizations

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Industry Analysis Market Reports News

Over 90 firms are actively involved in providing in silico services for drug discovery of different types of biologics; of these, over 30 players claim to have the capabilities to offer services for all steps of discovery

Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads. in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules against hundreds of biological targets, thereby, allowing significant reductions in the investment of both time and resources.

The USD 124 million (by 2030) financial opportunity within the in silico Drug Discovery market for large molecules has been analyzed across the following segments:

Key Drug Discovery Steps

  • Target Identification
  • Target Validation
  • Hit Generation
  • Hit-to-Lead
  • Lead Optimization

Type of Large Molecule

  • Antibodies
  • Proteins
  • Peptides
  • Nucleic Acids
  • Vectors

Company Size

  • Small
  • Mid-sized
  • Large

Target therapeutic Area

  • Autoimmune Disorders
  • Blood Disorders
  • Cardiovascular Disorders
  • Gastrointestinal and Digestive Disorders
  • Hormonal Disorders
  • Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
  • Infectious Diseases
  • Metabolic Disorders
  • Mental Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Respiratory Disorders
  • Skin Disorders
  • Urogenital Disorders
  • Others

Type of Sponsor

  • Industry Players
  • Non-Industry Players

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific

For more information, please visit https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

The In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules, 2020-2030, report features the following companies, which we identified to be key players in this domain:   

  • Abzena
  • BioDuro
  • BioNTech
  • ChemPartner
  • Creative Biostructure
  • GenScript
  • LakePharma
  • Sundia MediTech
  • Sygnature Discovery
  • Viva Biotech

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Market Landscape
  5. Key Insights
  6. Company Profiles
  7. Company Competitiveness Analysis
  8. Key Opportunity Areas
  9. Emerging Business Models and Strategies
  10. Case study: comparison of drug discovery processes of small molecules and large molecules
  11. Survey insights
  12. Cost saving analysis
  13. Market Forecast
  14. In silico tools and upcoming trends in drug discovery
  15. Executive Insights
  16. Appendix 1: Tabulated Data
  17. Appendix 2: List of Companies and Organizations
  18. Appendix 3: Non-Computational Methods for Drug Discovery

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Industry Analysis Market Reports News

Presently, 260 drug candidates are being evaluated in clinical / preclinical stages for the treatment of a wide variety of disease indications; the US has emerged as the major hub for microbiome-based research

The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine.

Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.

The USD 4 billion (by 2030) financial opportunity within the Microbiome Therapeutics (Tx) Market And Diagnostics (Dx) Markets, has been analyzed across the following segments:

Type of Therapy (Tx)

  • Prescription Drug
  • Prebiotics

Type of Molecule (Tx)

  • Small Molecules
  • Biologics

Target Indication (Tx+Dx)

  • Acne Vulgaris
  • Atopic Dermatitis
  • Clostridium difficile Infection
  • Colorectal Cancer
  • Crohn’s Disease
  • Diabetes
  • Irritable Bowel Syndrome
  • Lactose Intolerance
  • Lung Cancer
  • Nonalcoholic steatohepatitis (NASH)
  • Obesity
  • Ulcerative colitis

Therapeutic Area (Tx+Dx)

  • Autoimmune Disorders
  • Dental Disorders
  • Digestive and Gastrointestinal Disorders
  • Dermatological Disorders
  • Infectious Disease
  • Metabolic Disorders
  • Oncology
  • Others

Key Geographical Regions (Tx+Dx)

  • North America
  • Europe
  • Asia-Pacific and Rest of the World

 

The Human Microbiome Market, 2019-2030 report features the following companies, which we identified to be key players in this domain:

Key Players:

  • 4D Pharma
  • Armata Pharmaceuticals
  • Evelo Biosciences
  • Rebiotix (Acquired by Ferring Pharmaceuticals)
  • Seres Therapeutics
  • Vedanta Biosciences

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Microbiome Therapeutics: Market Landscape
  5. Company and Drug Profiles
  6. Microbiome Diagnostics: Market Landscape
  7. Fecal Microbiota Therapy (FMT)
  8. Attractiveness Competitiveness (AC) Matrix
  9. Microbiome Related Initiatives of Big Pharmaceutical Players
  10. Start-up Health Indexing
  11. Key Therapeutics Areas
  12. Funding and Investment Analysis
  13. Contract Services for Microbiome Therapeutics
  14. Big Data and Microbiome Therapeutics
  15. Microbiome Therapeutics: Market Forecast and Opportunity Analysis
  16. Microbiome Diagnostics: Market Forecast and Opportunity Analysis
  17. Fecal Microbiota Therapies: Market Forecast and Opportunity Analysis
  18. Case Study: Microbiome-based Products in Other Industries
  19. Concluding Remarks
  20. Executive Insights
  21. Appendix I: Tabulated Data
  22. Appendix II: List of Companies and Organizations

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Industry Analysis Market Reports News

Over 180 companies from different regions across the globe presently claim to provide services for the development of companion diagnostic tests, claims Roots Analysis

It is estimated that around 80% of innovator companies rely on external companion diagnostic developers, mostly owing to the lack of the required in-house expertise. On the other hand, there are numerous contract service providers, offering vast portfolios of services for diagnostic test / assay development. Such companies are known to possess extensive technical knowledge, and experience in working with cutting-edge analytical tools and technologies, such as in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR).

The USD 800+ million (by 2030) financial opportunity within the Companion Diagnostics Development Services Market has been analysed across the following segments:

Type of Service Offered

  • Feasibility Studies
  • Assay Development
  • Analytical Validation
  • Clinical Validation

Type of Assay Technique Used

  • in situ hybridization / Immunohistochemistry
  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Others

Key geographical regions

  • North America
  • Europe
  • Asia Pacific

The report features inputs from eminent industry stakeholders, according to whom the development of companion diagnostics is largely outsourced, owing to the exorbitant costs associated with the setting-up of in-house expertise / capabilities. The report includes detailed transcripts of discussions held with the following experts:

  • Anton Iliuk (President and Chief Technology Officer, Tymora Analytica)
  • Paul Kortschak (Senior Vice President, Novodiax)
  • Pablo Ortiz (Chief Executive officer, OWL Metabolomics)
  • Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

For more information, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Market Landscape
  5. Company Profiles
  6. Partnerships and Collaborations
  7. Likely Partner Analysis
  8. Company Competitiveness Analysis
  9. Stakeholder Needs Analysis
  10. Value Chain Analysis
  11. Clinical Research on Cancer Biomarkers: Big Pharma Perspective
  12. Market Forecast And Opportunity Analysis
  13. Executive Insights
  14. Appendix 1: Tabulated Data
  15. Appendix 2: List of Companies and Organizations

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Industry Analysis Market Reports News

The “Ophthalmic Drugs Contract Manufacturing Market, 2020-2030” report features an extensive study of the contract services market for ophthalmic APIs and drug FDFs (including ophthalmic drops, emulsions, gels, injections, lotions, ointments, suspensions, and tablets / capsules) – Roots Analysis

Ophthalmic diseases, such as age-related macular degeneration, cataract, diabetic retinopathy, dry eye and glaucoma, are considered among the leading causes of vision loss across the globe.

Key Inclusions

  • A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters, such as year of establishment, company size, geographical location, scale of operation (preclinical, pilot, clinical, and commercial), type of product (APIs and FDFs), type of FDF manufactured (solids, semi-solids, liquids, suspensions, and injectables), type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, sachets / pouches, blister packing, and other forms), type of service(s) offered (pre-formulation, drug formulation, method validation, process development, analytical testing, stability studies, technology transfer, scale-up, fill / finish, and regulatory support), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.
  • A company competitiveness analysis, highlighting prominent ophthalmic drug contract manufacturers based on supplier strength (which was calculated considering the size of employee base of a company and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities, and number of regulatory accreditations / certifications)..
  • Elaborate profiles of key players based in North America, Europe and Asia-Pacific that offer a diverse range of capabilities for the development, manufacturing and packaging of ophthalmic drug products. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.
  • A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products, highlighting prevalent trends across parameters, such as current trial status, trial registration year, enrolled patient population and trial location, phase of development, study design, leading industry and non-industry players (in terms of number of trials undertaken / conducted), study focus, and key disease indications (in terms of number of trials undertaken / conducted).
  • An informed estimate of the annual commercial demand for ophthalmic APIs and drug FDFs (in million litres), taking into account the top 30 small molecule-based ophthalmic drugs; the analysis takes into consideration the target patient population, dosing frequency and dose strength of the aforementioned products. The annual clinical demand for ophthalmic drug products was also estimated, taking into account ongoing and planned clinical trials.
  • A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized, and large-sized CMOs) in the market, based on data gathered via secondary and primary research. It also provides the likely distribution of the global ophthalmic product-related manufacturing capacity available across different types of companies (small-sized, mid-sized, and large-sized), scales of operation (preclinical, clinical and commercial), types of FDFs manufactured (ampoules / vials, glass / plastic bottles, and ointment tubes), and key geographical regions (North America, Europe, and Asia-Pacific).
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to ophthalmic drug developers.
  • A discussion on the emerging trends and potential market drivers, such as the growing ophthalmic drugs / therapies pipeline, rise in outsourcing activity for sterile manufacturing operations, adoption of innovative technologies and increasing opportunities in the Asia-Pacific region, which are likely to impact the evolution of the market in the coming years.
  • A detailed list of over 55 ophthalmic medical device contract manufacturers, along with information on year of establishment, company size, geographical location, key application area(s) (diagnostics, drug delivery, therapeutics, and others), type of manufacturing service(s) offered (design, component manufacturing, assembly, prototype development, sterilization, quality assurance, and packaging), type of additional service(s) offered (consultancy, documentation, inspection / testing, labelling, logistics, project management, regulatory support, repair, warehouse / storage, and others), scale of operation (pilot and commercial), device class-related expertise (class I, class II and class III), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

Type of product

  • Ophthalmic API
  • Ophthalmic drug FDF

Type of FDF manufactured

  • Solid
  • Semi-solid
  • Liquid / suspension

Type of primary packaging

  • Ampoule / vial
  • Glass / plastic bottle
  • Ointment tube
  • Blister packing
  • Other forms

Scale of manufacturing

  • Clinical
  • Commercial

Company size

  • Small
  • Mid-sized
  • Large
  • Very large

Target disease indication

  • Age-related macular degeneration
  • Dry eye
  • Glaucoma
  • Other disease segments

Key geographical regions

  • North America (US, Canada and Mexico)
  • Europe (UK, Germany, France, Spain, Italy and rest of Europe)
  • Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)
  • Rest of the world

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Industry Analysis Market Reports News

More than 80 companies currently claim to offer manufacturing related services, at different scales of operations, for a variety of oligonucleotide-based products, claims Roots Analysis

Several big pharma companies are known to outsource more than half of their clinical-stage oligonucleotide manufacturing operations. Anticipating a sharp rise in demand, oligonucleotide manufacturers are increasingly consolidating their portfolios, building new capabilities and expanding their respective capacities, mostly through acquisitions, in order to gain a competitive edge.

The USD 5.8 billion (by 2030) financial opportunity within the  Oligonucleotide Synthesis, Modification And Purification Services Market has been analysed across the following segments:

Type of manufacturing

  • Custom manufacturing
  • Large-scale manufacturing

Type of Oligonucleotides manufactured

  • Antisense Oligonucleotides
  • miRNAs
  • shRNAs
  • siRNAs
  • Other Oligonucleotides

Scale of operation

  • Clinical
  • Commercial

Purpose of production

  • In-house
  • Outsourced

Target therapeutic area

  • Autoimmune Disorders
  • Cardiovascular Disorders
  • Genetic Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Neuromuscular Disorders
  • Oncological Disorders
  • Ophthalmic Disorders
  • Other Therapeutic Areas

Size of manufacturer

  • Small
  • Mid-sized
  • Large

Key Geographical Region

  • North America
  • Europe
  • Asia-Pacific and Rest of the World

The Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Agilent Technologies
  • Ajinomoto Bio-Pharma Services
  • BioSpring
  • CordenPharma
  • Integrated DNA Technologies
  • Kaneka Eurogentec
  • LGC Biosearch Technologies
  • Microsynth
  • Nitto Denko Avecia
  • Sigma Aldrich
  • Thermo Fisher Scientific
  • Trilink Biotechnologies

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Market Landscape: Oligonucleotide Manufacturers (Research and Diagnostic Applications)
  5. Market Landscape: Oligonucleotide Manufacturers (Therapeutic Applications)
  6. Company Competitiveness Analysis: Oligonucleotide Manufacturers (Research and Diagnostic Applications)
  7. Company Competitiveness Analysis: Oligonucleotide Manufacturers (Therapeutic Applications)
  8. Company Profiles: Oligonucleotide Manufacturers (Research and Diagnostic Applications)
  9. Company Profiles: Oligonucleotide Manufacturers (Therapeutic Applications)
  10. Partnerships and Collaborations
  11. Recent Expansions
  12. Clinical Trial Analysis
  13. Capacity Analysis
  14. Demand Analysis
  15. Market Sizing and Opportunity Analysis
  16. Swot Analysis
  17. Survey Analysis
  18. Executive Insights
  19. Concluding Remarks
  20. Appendix 1: Tabulated Data
  21. Appendix 2: List of Companies and Organizations

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
Industry Analysis Market Reports News

Targeted Protein Degradation Market Worth USD 3.6 billion by 2030 | Roots Analysis

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:

Market Segment:  

Type of payment of licensing agreements

  • Upfront payments
  • Milestone payments

Type of protein degrader

  • Degronimids
  • PROTACs
  • SARDs / SERDs
  • Specific BET and DUB inhibitors
  • Other protein degraders

Therapeutic area

  • Neurodegenerative disorders
  • Oncological disorders
  • Other therapeutic areas

Route of administration 

  • Oral
  • Intravenous
  • Other routes

Key geographical region

  • North America
  • Europe
  • Asia-Pacific

The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:

Market Key Players:

  • Arvinas
  • Captor Therapeutics
  • Celgene
  • Genetech
  • Kymera Therapeutics
  • Mission Therapeutics
  • Progenra
  • Radius Health
  • Sanofi Genzyme
  • Zenopharm

Table of Contents

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Current Market Landscape
  5. Company Profiles
  6. Clinical Trial Analysis
  7. KOL Analysis
  8. Publication Analysis
  9. Funding and Investment Analysis
  10. Partnerships and Collaborations
  11. Market Sizing and Opportunity Analysis
  12. Executive Insights
  13. Concluding Remarks
  14. Appendix 1: Tabulated Data
  15. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]